|
Comparison
of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer
Susak
YM, Zemskov VS, Yaremchuk OY, Kravchenco OB, Yatsyk IM, Korsh OB
Department
of General Surgery, Ukrainian State Medical University, Kiev, Ukraine
Ninety
six colorectal carcinoma patients were included in a randomised study, 48 were
treated with Ukrain monotherapy (15 with metastatic and 33 with nonmetastatic
colorectal carcinoma) and 48 with 5-fluorouracil (5-FU) and X-ray therapy (the
same randomised groups).
The results of therapy including clinical, haematological, immunological and
biochemical parameters show that Ukrain has favourable properties in the
treatment of colon and rectal cancer as a monotherapy because of its
malignotoxic and immunomodulating action.
Objective response rate in the group of metastatic colorectal cancer treated by
Ukrain was 40%.
There was no registered tumour regression in the group treated by 5-FU.
Operability is strongly facilitated by pretreatment with Ukrain.
The survival rate (up to 21 months) in the Ukrain-treated patients with
nonmetastatic colorectal cancer was 78.6% and 33.3% in a corresponding control
group.
Ukrain is a new effective drug in the therapy of colorectal cancer.
It can be useful both for the therapy of metastatic colorectal cancer and for
neoadjuvant therapy of nonmetastatic colorectal cancer.
PMID:
8899313 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8899313&dopt=Abstract
|
